Scientists Just Engineered a Plant That Produces Five Psychedelics at Once
Is this the world’s most illegal plant? Researchers at the Weizmann Institute of Science in Israel have genetically engineered tobacco plants capable of producing five distinct psychedelic compounds simultaneously. The compounds include psilocin and psilocybin from magic mushrooms, DMT from the ayahuasca plant, and bufotenin and 5-methoxy-DMT secreted by the Sonoran Desert toad. The study was published this week in the journal Science Advances.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Takeaway | Detail |
|---|---|
| Compounds produced | Psilocin, psilocybin, DMT, bufotenin, 5-MeO-DMT |
| Host plant | Tobacco |
| Research institution | Weizmann Institute of Science, Israel |
| Primary goal | Sustainable, scalable production for therapeutic research |
| Inheritance | Intentionally blocked — compounds stay in leaves only |
| Conservation benefit | Reduces pressure on over-harvested natural source organisms |
Why This Research Matters for Mental Health
The goal is not recreational. Co-lead researcher Paula Berman stressed the therapeutic potential of these substances. Scientists inserted the active genes of five tryptamines — a class of hallucinogens — directly into tobacco leaves. The result is a single plant that bridges three separate biological kingdoms. That is a first.
For the mental health community, this development carries real weight. Psilocybin therapy has already shown promise in treating depression and other mood disorders. DMT and 5-MeO-DMT are drawing serious clinical interest as well. A more sustainable, scalable way to produce these compounds could accelerate access to therapies that are still difficult to study because supply chains remain complicated and unreliable.
Conservation and Scalability Go Hand in Hand
The research also addresses a growing ecological problem. The Sonoran Desert toad faces mounting threats from habitat loss and poaching. The slow-growing ayahuasca plant faces similar pressures as demand from wellness tourism rises. Conventional lab synthesis of these compounds is often complex and time intensive.
Senior author Asaph Aharoni described it plainly: “In one leaf, we get five different psychedelics from three different kingdoms.” The team intentionally prevented the modified traits from passing to the next generation. That decision keeps the research contained and reduces the risk of misuse.
Still Early Days
The concentrations produced remain lower than those found in natural source organisms. This is a proof of concept, not a ready-to-use production system. Still, the implications for therapeutic research are significant.
As psychedelic assisted therapy continues to gain clinical credibility, the infrastructure supporting it must grow too. This research represents a meaningful step toward building that foundation.
Related provider: Biltmore Restorative
Related provider: Conscious Pharmacist ‘ Algarve, Portugal
Related provider: MindScape Retreat ‘ Cozumel, Mexico
Related provider: MedBridge WV — Kingwood
